82_FR_39602 82 FR 39443 - Government-Owned Inventions; Availability for Licensing

82 FR 39443 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 159 (August 18, 2017)

Page Range39443-39444
FR Document2017-17438

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 159 (Friday, August 18, 2017) 
[Federal Register Volume 82, Number 159 (Friday, August 18, 2017)]
[Notices]
[Pages 39443-39444]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-17438]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Peter Soukas, J.D., (301) 594-8730; 
peter.soukas@nih.gov. Licensing information and copies of the patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD, 20852; tel. (301) 496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Development of a Transferrable Norwalk Virus Epitope and Detector 
Monoclonal Antibody

Description of Technology

    Noroviruses are now recognized as the major cause of non-bacterial 
gastroenteritis in all age groups, and efforts are underway to develop 
an effective vaccine. The lack of a robust cell culture system for 
human noroviruses has complicated vaccine development. Hence, norovirus 
virus like particles (VLPs) have played an important role in the 
understanding of virus structure, immune response, antigenic diversity, 
and vaccine design. The development of monoclonal antibodies (MAbs) 
against norovirus VLPs has allowed the identification and 
characterization of key antigenic sites of the virus capsid and 
facilitated the development of diagnostic assays. During 
characterization of a panel of MAbs raised against Norwalk virus (NV), 
a prototype norovirus strain, the inventors identified a monoclonal 
antibody (MAbNV10) that proved useful in the identification of NV in 
tissue and in the characterization of an insertion site in the feline 
calicivirus (FCV) genome. The inventors mapped the precise binding site 
of the MAb by peptide screening and discovered that the epitope could 
be expressed when fused to other proteins. The sequence of this peptide 
(epitope) along with the detector antibody could be used as a new way 
to tag proteins for functional studies. The small size of the linear 
epitope, along with the strong avidity of the detector monoclonal 
antibody makes this system especially useful for many techniques, 
including immunofluorescence, Western blot, immunoprecipitation 
(including ``pulldown'' assays), and immunohistochemistry. The 
inventors' epitope system may be comparable to that of the HA tag of 
influenza virus that is widely used in molecular biology.
    This technology is further described in Parra et al., ``Mapping and 
modeling of a strain-specific epitope in the Norwalk virus capsid inner 
shell,'' Virology. 2016 May;492:232-41. doi: 10.1016/
j.virol.2016.02.019. Epub 2016 Mar 21.
    Materials available for licensing comprise: (1) Hybridoma cell line 
NV10, (2) Plasmid expressing NV10 epitope as positive control, and (3) 
Plasmid expressing the NV10 scFV.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

 Diagnostics
 Vaccines

Competitive Advantages

 Cross-reactive norovirus antibody

[[Page 39444]]

 Ease of manufacture
 Efficient norovirus detection

Development Stage

 In vivo data available (animal)

    Inventors: Kim Green, Ph.D. (NIAID); Gabriel Parra, Ph.D. (NIAID); 
Stanislav Sosnovtsev, Ph.D. (NIAID); Karin Bok, Ph.D. (NIAID); Carlos 
Sandoval-Jaime, Ph.D. (NIAID); Eugenio Abente, Ph.D. (NIAID)
    Intellectual Property: HHS Reference No. E-101-2013/0.
    Licensing Contact: Peter Soukas, J.D., (301) 594-8730; 
peter.soukas@nih.gov. Collaborative Research Opportunity: The National 
Institute of Allergy and Infectious Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize norovirus 
diagnostics or vaccines. For collaboration opportunities, please 
contact Peter Soukas, J.D., (301) 594-8730; peter.soukas@nih.gov.

    Dated: August 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-17438 Filed 8-17-17; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 159 / Friday, August 18, 2017 / Notices 39443 (Catalogue of Federal Domestic Assistance National Institute on Alcohol Abuse and gastroenteritis in all age groups, and Program No. 93.242, Mental Health Research Alcoholism, National Institutes of Health, efforts are underway to develop an Grants, National Institutes of Health, HHS) 5365 Fishers Lane, Room 2085, Rockville, effective vaccine. The lack of a robust MD 20852, (301) 451–2067 srinivar@ Dated: August 14, 2017. cell culture system for human mail.nih.gov. Melanie J. Pantoja, noroviruses has complicated vaccine (Catalogue of Federal Domestic Assistance development. Hence, norovirus virus Program Analyst, Office of Federal Advisory Program Nos. 93.271, Alcohol Research like particles (VLPs) have played an Committee Policy. Career Development Awards for Scientists [FR Doc. 2017–17430 Filed 8–17–17; 8:45 am] and Clinicians; 93.272, Alcohol National important role in the understanding of BILLING CODE 4140–01–P Research Service Awards for Research virus structure, immune response, Training; 93.273, Alcohol Research Programs; antigenic diversity, and vaccine design. 93.891, Alcohol Research Center Grants; The development of monoclonal DEPARTMENT OF HEALTH AND 93.701, ARRA Related Biomedical Research antibodies (MAbs) against norovirus HUMAN SERVICES and Research Support Awards., National VLPs has allowed the identification and Institutes of Health, HHS) characterization of key antigenic sites of National Institutes of Health Dated: August 14, 2017. the virus capsid and facilitated the Melanie J. Pantoja, development of diagnostic assays. National Institute on Alcohol Abuse During characterization of a panel of Program Analyst, Office of Federal Advisory and Alcoholism; Notice of Closed Committee Policy. MAbs raised against Norwalk virus Meetings (NV), a prototype norovirus strain, the [FR Doc. 2017–17428 Filed 8–17–17; 8:45 am] Pursuant to section 10(d) of the BILLING CODE 4140–01–P inventors identified a monoclonal Federal Advisory Committee Act, as antibody (MAbNV10) that proved useful amended, notice is hereby given of the in the identification of NV in tissue and following meetings. DEPARTMENT OF HEALTH AND in the characterization of an insertion The meetings will be closed to the HUMAN SERVICES site in the feline calicivirus (FCV) public in accordance with the genome. The inventors mapped the provisions set forth in sections National Institutes of Health precise binding site of the MAb by 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., peptide screening and discovered that as amended. The grant applications and Government-Owned Inventions; the epitope could be expressed when the discussions could disclose Availability for Licensing fused to other proteins. The sequence of confidential trade secrets or commercial AGENCY: National Institutes of Health, this peptide (epitope) along with the property such as patentable material, HHS. detector antibody could be used as a and personal information concerning ACTION: Notice. new way to tag proteins for functional individuals associated with the grant studies. The small size of the linear applications, the disclosure of which SUMMARY: The invention listed below is epitope, along with the strong avidity of would constitute a clearly unwarranted owned by an agency of the U.S. the detector monoclonal antibody makes invasion of personal privacy. Government and is available for this system especially useful for many licensing to achieve expeditious techniques, including Name of Committee: National Institute on Alcohol Abuse and Alcoholism Initial commercialization of results of immunofluorescence, Western blot, Review Group Epidemiology, Prevention and federally-funded research and immunoprecipitation (including Behavior Research Review Subcommittee. development. Foreign patent ‘‘pulldown’’ assays), and Date: October 23, 2017. applications are filed on selected immunohistochemistry. The inventors’ Time: 8:30 a.m. to 5:00 p.m. inventions to extend market coverage epitope system may be comparable to Agenda: To review and evaluate grant for companies and may also be available applications. that of the HA tag of influenza virus that for licensing. is widely used in molecular biology. Place: National Institutes of Health, National Institute on Alcohol Abuse and FOR FURTHER INFORMATION CONTACT: This technology is further described Alcoholism, Terrace Level Conference Peter Soukas, J.D., (301) 594–8730; in Parra et al., ‘‘Mapping and modeling Rooms, 5635 Fishers Lane, Rockville, MD peter.soukas@nih.gov. Licensing of a strain-specific epitope in the 20852. information and copies of the patent Norwalk virus capsid inner shell,’’ Contact Person: Anna Ghambaryan, M.D., applications listed below may be Virology. 2016 May;492:232–41. doi: Ph.D., Scientific Review Officer, Extramural obtained by communicating with the 10.1016/j.virol.2016.02.019. Epub 2016 Project Review Branch, Office of Extramural indicated licensing contact at the Activities, National Institute on Alcohol Mar 21. Abuse and Alcoholism, National Institutes of Technology Transfer and Intellectual Materials available for licensing Health, 5635 Fishers Lane, Room 2019, Property Office, National Institute of comprise: (1) Hybridoma cell line NV10, Rockville, MD 20852, 301–443–4032, Allergy and Infectious Diseases, 5601 (2) Plasmid expressing NV10 epitope as anna.ghambaryan@nih.gov. Fishers Lane, Rockville, MD, 20852; tel. positive control, and (3) Plasmid Name of Committee: National Institute on (301) 496–2644. A signed Confidential expressing the NV10 scFV. Alcohol Abuse and Alcoholism Initial Disclosure Agreement will be required This technology is available for Review Group Clinical, Treatment and to receive copies of unpublished patent licensing for commercial development Health Services Research Review applications. in accordance with 35 U.S.C. 209 and 37 Subcommittee. CFR part 404, as well as for further Date: November 1, 2017. SUPPLEMENTARY INFORMATION: Technology description follows. development and evaluation under a Time: 8:30 a.m. to 5:00 p.m. mstockstill on DSK30JT082PROD with NOTICES Agenda: To review and evaluate grant research collaboration. Development of a Transferrable applications. Potential Commercial Applications Place: National Institutes of Health, Norwalk Virus Epitope and Detector National Institute on Alcohol Abuse and Monoclonal Antibody • Diagnostics Alcoholism, Terrace Level Conference Room • Vaccines Description of Technology 508, 5635 Fishers Lane, Rockville, MD 20852 Contact Person: Ranga V. Srinivas, Ph.D. Noroviruses are now recognized as Competitive Advantages Chief Extramural Project Review, Branch the major cause of non-bacterial • Cross-reactive norovirus antibody VerDate Sep<11>2014 17:47 Aug 17, 2017 Jkt 241001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\18AUN1.SGM 18AUN1

39444 Federal Register / Vol. 82, No. 159 / Friday, August 18, 2017 / Notices • Ease of manufacture Democracy Boulevard, Bethesda, MD 20892, Agenda: To review and evaluate grant • Efficient norovirus detection (Telephone Conference Call). applications. Contact Person: Rahat (Rani) Khan, Ph.D., Place: National Institutes of Health, Two Development Stage Scientific Review Officer, Office of Scientific Democracy Plaza, Suite 920, 6707 Democracy • In vivo data available (animal) Review, National Center for Advancing, Boulevard, Bethesda, MD 20892, (Virtual Translational Sciences, 6701 Democracy Meeting). Inventors: Kim Green, Ph.D. (NIAID); Blvd., Rm 1078, Bethesda, MD 20892, 301– Contact Person: John K. Hayes, Ph.D., Gabriel Parra, Ph.D. (NIAID); Stanislav 894–7319, khanr2@csr.nih.gov. Scientific Review Officer, 6707 Democracy Sosnovtsev, Ph.D. (NIAID); Karin Bok, (Catalogue of Federal Domestic Assistance Blvd., Suite 959, Democracy Two, Bethesda, Ph.D. (NIAID); Carlos Sandoval-Jaime, Program Nos. 93.859, Pharmacology, MD 20892, (301) 451–3398, hayesj@ Ph.D. (NIAID); Eugenio Abente, Ph.D. Physiology, and Biological Chemistry mail.nih.gov. (NIAID) Research; 93.350, B—Cooperative Dated: August 14, 2017. Intellectual Property: HHS Reference Agreements; 93.859, Biomedical Research and Research Training, National Institutes of David Clary, No. E–101–2013/0. Licensing Contact: Peter Soukas, J.D., Health, HHS) Program Analyst, Office of Federal Advisory (301) 594–8730; peter.soukas@nih.gov. Committee Policy. Dated: August 14, 2017. [FR Doc. 2017–17429 Filed 8–17–17; 8:45 am] Collaborative Research Opportunity: David Clary, The National Institute of Allergy and BILLING CODE 4140–01–P Infectious Diseases is seeking statements Program Analyst, Office of Federal Advisory Committee Policy. of capability or interest from parties [FR Doc. 2017–17427 Filed 8–17–17; 8:45 am] DEPARTMENT OF HOMELAND interested in collaborative research to BILLING CODE 4140–01–P SECURITY further develop, evaluate or commercialize norovirus diagnostics or vaccines. For collaboration U.S. Citizenship and Immigration DEPARTMENT OF HEALTH AND Services opportunities, please contact Peter HUMAN SERVICES Soukas, J.D., (301) 594–8730; [OMB Control Number 1615–0120] peter.soukas@nih.gov. National Institutes of Health Dated: August 3, 2017. Agency Information Collection Suzanne Frisbie, National Institute of Biomedical Activities; Extension, Without Change, Imaging and Bioengineering; Notice of of a Currently Approved Collection; Deputy Director, Technology Transfer and Intellectual Property Office, National Institute Closed Meetings Free Training for Civics and of Allergy and Infectious Diseases. Citizenship of Adults, Form G–1190; Pursuant to section 10(d) of the Civics and Citizenship Toolkit, Form [FR Doc. 2017–17438 Filed 8–17–17; 8:45 am] Federal Advisory Committee Act, as G–1515 BILLING CODE 4140–01–P amended, notice is hereby given of the following meetings. AGENCY: U.S. Citizenship and The meetings will be closed to the Immigration Services, Department of DEPARTMENT OF HEALTH AND public in accordance with the Homeland Security. HUMAN SERVICES provisions set forth in sections ACTION: 30-Day notice. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., National Institutes of Health SUMMARY: The Department of Homeland as amended. The grant applications and the discussions could disclose Security (DHS), U.S. Citizenship and National Center for Advancing confidential trade secrets or commercial Immigration Services (USCIS) will be Translational Sciences; Notice of property such as patentable material, submitting the following information Closed Meeting and personal information concerning collection request to the Office of Pursuant to section 10(d) of the individuals associated with the grant Management and Budget (OMB) for Federal Advisory Committee Act, as applications, the disclosure of which review and clearance in accordance amended, notice is hereby given of the would constitute a clearly unwarranted with the Paperwork Reduction Act of following meeting. invasion of personal privacy. 1995. The purpose of this notice is to The meeting will be closed to the allow an additional 30 days for public Name of Committee: National Institute of public in accordance with the Biomedical Imaging and Bioengineering comments. provisions set forth in sections Special Emphasis Panel; NIBIB Team-Based DATES: The purpose of this notice is to 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., R25 Review (2018/01). allow an additional 30 days for public as amended. The contract proposals and Date: September 28, 2017. comments. Comments are encouraged the discussions could disclose Time: 09:00 a.m. to 5:00 p.m. and will be accepted until September confidential trade secrets or commercial Agenda: To review and evaluate grant 18, 2017. This process is conducted in property such as patentable material, applications. Place: National Institutes of Health, Two accordance with 5 CFR 1320.10. and personal information concerning ADDRESSES: Written comments and/or Democracy Plaza, Suite 920, 6707 Democracy individuals associated with the contract Boulevard, Bethesda, MD 20892, (Virtual suggestions regarding the item(s) proposals, the disclosure of which Meeting). contained in this notice, especially would constitute a clearly unwarranted Contact Person: Ruixia Zhou, Ph.D., regarding the estimated public burden invasion of personal privacy. Scientific Review Officer, 6707 Democracy and associated response time, must be Name of Committee: National Center for Boulevard, Democracy Two Building, Suite directed to the OMB USCIS Desk Officer mstockstill on DSK30JT082PROD with NOTICES Advancing Translational Sciences Special 957, Bethesda, MD 20892, (301) 496–4773, zhour@mail.nih.gov. via email at dhsdeskofficer@ Emphasis Panel Contract Review. omb.eop.gov. All submissions received Date: September 12, 2017. Name of Committee: National Institute of Time: 1:00 p.m. to 4:00 p.m. Biomedical Imaging and Bioengineering must include the agency name and the Agenda: To review and evaluate contract Special Emphasis Panel; T32–R25 Review OMB Control Number 1615–0120 in the proposals. Meeting (2018/01). subject line. Place: National Institutes of Health, One Date: October 24, 2017. You may wish to consider limiting the Democracy Plaza, Room 1037, 6701 Time: 09:30 a.m. to 7:00 p.m. amount of personal information that you VerDate Sep<11>2014 17:47 Aug 17, 2017 Jkt 241001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\18AUN1.SGM 18AUN1


Document Created: 2017-08-18 07:40:20
Document Modified: 2017-08-18 07:40:20
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactPeter Soukas, J.D., (301) 594-8730; [email protected] Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. (301) 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 39443 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR